OncoDNA S.A. products

Oncodeep® is a comprehensive biomarker test designed to guide treatment of advanced, metastatic solid tumors. When your patients are diagnosed with a rare cancer type or an aggressive cancer, when chemotherapy doesn`t work or when cancer comes back, OncoDEEP® can provide you with clear clinical guidance. Starting from a small sample of tumor tissue, our biomarker test is able to pinpoint the therapeutic vulnerabilities of a tumor and identify appropriate cancer treatment options in a fast turnaround.

OncoSELECT: Smart liquid biopsy panels with selected key genes per tumor type. The Liquid Biopsy Solution For Disease Monitoring Or Therapeutic Decision. OncoSELECT is a fast and minimally invasive analysis of circulating tumor DNA from a blood sample for lung (NSCLC), colorectal and breast (HR+ or HER2+) cancer patients. It is the perfect solution to identify therapeutic options for cancer patients not able to have their tumor biopsied or whose biopsy is too old. It can be used as a tool to detect treatment resistance to targeted therapies (before first-line to check the heterogeneity of the disease, or during/after treatment to check for acquired resistance mutations), as well as for monitoring cancer progression.

OncoFOLLOW: The first personalised liquid biopsy in the market. Monitor the progression and detect lack of response. OncoFOLLOW is a test based on the analysis of circulating tumor DNA in blood. It is used to monitor the progression of the tumor (burden of the disease) and to detect lack of response or resistance to treatment as soon as it appears. This assay is customised for each patient, as it analyses up to 15 variants previously identified in the tumour of the patient. In addition, it sequences a fixed panel of 40 genes associated with response/resistance to targeted therapies and immunotherapy, and/or frequently mutated in cancer. In 2013, OncoDNA became the first company to launch a personalized liquid biopsy test.